Plain-English translation of NCT05216432 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This is an early-stage trial testing a new medication called designed specifically for cancers with a PIK3CA gene mutation. Depending on your cancer type, you may take this medication alone, or in combination with hormone therapy and other cancer drugs. The trial aims to find the right dose, understand how safe the medication is, and see how well it works against your cancer.
Many advanced cancers have a PIK3CA mutation that helps the cancer grow. Current treatments don't specifically target this mutation, so this trial exists to test whether this medication can work better for patients whose tumors have this specific genetic change.
You likely qualify if…
You likely don't qualify if…
You will take the medication by mouth, possibly in combination with other drugs depending on which arm of the trial you join. You'll have regular visits to the clinic for blood tests, physical exams, and imaging scans to monitor how the cancer is responding and check for side effects. Early parts of the trial involve frequent visits to find the right dose; later parts may have a more stable schedule. The trial is still recruiting, so the total length of treatment will depend on how well the medication works for you and how you tolerate it.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
United States